Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chromatin analysis of multiple myeloma cells following CBP/p300 inhibition and degradation (ChIP-Seq)

ABSTRACT: Chromatin analysis of multiple myeloma cells following CBP/p300 inhibition and degradation (ChIP-Seq)

PROVIDER: PRJNA672966 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12926200.fastq.gz	Fastqsanger.gz
	SRR12926201.fastq.gz	Fastqsanger.gz
	SRR12926189.fastq.gz	Fastqsanger.gz
	SRR12926190.fastq.gz	Fastqsanger.gz
	SRR12926191.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 13

Similar Datasets

Chromatin analysis of multiple myeloma cells following CBP/p300 inhibition and degradation

Project description:Chromatin analysis of multiple myeloma cells following CBP/p300 inhibition and degradation

| PRJNA672959 | ENA

Chromatin analysis of multiple myeloma cells following CBP/p300 inhibition and degradation (ATAC-Seq)

Project description:Chromatin analysis of multiple myeloma cells following CBP/p300 inhibition and degradation (ATAC-Seq)

| PRJNA672963 | ENA

Chromatin analysis of multiple myeloma cells following CBP/p300 inhibition and degradation (RNA-Seq)

Project description:Chromatin analysis of multiple myeloma cells following CBP/p300 inhibition and degradation (RNA-Seq)

| PRJNA672967 | ENA

Chromatin analysis of multiple myeloma cells following CBP/p300 inhibition and degradation (ChIP-Seq)

Project description:We performed H3K27ac ChIP-seq on MM.1S cells treated with A-485, GNE-781, and the combination of both, or with dCBP-1, and CBP & p300 ChIP on MM.1S cells.

2020-12-31 | GSE160335 | GEO

Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer

Project description:Prostate cancer is driven by oncogenic transcription factor enhanceosomes comprising chromatin and epigenetic regulators. The lysine acetyltransferases p300 and CBP are key cofactors that activate enhancers through histone acetylation. Here, we identify p300/CBP-mediated multisite acetylation of the histone H2B N-terminus (H2BNTac) as a defining feature of oncogenic enhanceosomes in androgen receptor (AR)-positive prostate cancer. p300/CBP are essential for AR and ERG transcriptional activity, and their dual degradation eliminates H2BNTac and H3K27ac marks at hyperactive enhancers more effectively than targeting either paralog or bromodomains alone. Cytotoxicity profiling across >900 cell lines revealed that tumors with high H2BNTac, including AR-positive prostate cancer, are selectively dependent on p300/CBP. In preclinical models, systemic p300/CBP degradation inhibited tumor growth, synergized with AR antagonists, and showed no evident toxicity. These findings position H2BNTac as a key epigenetic marker of enhancer addiction and support dual p300/CBP degradation as a promising therapy for enhancer-driven cancers.

2025-07-28 | PXD065292 | Pride

Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer

2025-07-28 | PXD065228 | Pride

Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer (ATAC-Seq)

Project description:Prostate cancer (PCa) is driven by oncogenic transcription factor enhanceosomes comprising chromatin and epigenetic regulators. The lysine acetyltransferases p300 and CBP are key cofactors that activate enhancers through histone acetylation. Here, we identify p300/CBP-mediated multisite acetylation of the histone H2B N-terminus (H2BNTac) as a defining feature of oncogenic enhanceosomes in androgen receptor (AR)-positive prostate cancerPCa. p300/CBP are essential for AR and ERG transcriptional activity, and their dual degradation eliminates H2BNTac and H3K27ac marks at hyperactive enhancers, leading to stronger suppression of oncogenic transcription more effectively than targeting either paralog or bromodomains alone. Cytotoxicity profiling across >900 cell lines revealed that tumors with high H2BNTac, including AR-positive prostate cancerPCa, are selectively dependent on p300/CBP. In preclinical models, systemic p300/CBP degradation inhibited tumor growth, synergized with AR antagonists, and showed no evident toxicity. These findings position H2BNTac as an key epigenetic marker of enhancer addiction and establish support dual p300/CBP degradation as a promising therapeutic strategypy for enhancer-driven cancers.

2025-06-26 | GSE255131 | GEO